Literature DB >> 2038728

Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers.

B Schmekel1, L Borgström, P Wollmer.   

Abstract

Pathophysiological studies have shown that the alveolocapillary transfer of small solutes is much faster in healthy smokers than in non-smokers. The effects of smoking on the pulmonary absorption of inhaled terbutaline were examined in normal subjects. Nine healthy smokers and 13 healthy non-smokers inhaled nebulised terbutaline and dry terbutaline powder on two study days. Plasma concentrations of terbutaline were measured up to 240 minutes after the inhalation. The plasma concentration of terbutaline rose much faster in smokers than in non-smokers, the mean time to peak terbutaline concentration being 17 minutes in the smokers and 50 minutes in the non-smokers. The peak plasma concentration was nearly twice as high in the smokers as in the non-smokers, being 21 mmol/l and 23 mmol/l for the dry powder inhalation and nebuliser respectively in the smokers and 12 mmol/l and 14 mmol/l in the non-smokers. It is concluded that smoking increases the rate of terbutaline absorption and the peak plasma concentration achieved. The rapid pulmonary absorption of terbutaline in smokers may affect the onset of action of the drug and the duration of its therapeutic effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2038728      PMCID: PMC463078          DOI: 10.1136/thx.46.4.225

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

1.  Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.

Authors:  L Borgström; L Nyberg; S Jönsson; C Lindberg; J Paulson
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

2.  Increased alveolar epithelial permeability in cigarette smokers.

Authors:  J G Jones; B D Minty; P Lawler; G Hulands; J C Crawley; N Veall
Journal:  Lancet       Date:  1980-01-12       Impact factor: 79.321

Review 3.  Solute permeability of the alveolar capillary barrier.

Authors:  M P Barrowcliffe; J G Jones
Journal:  Thorax       Date:  1987-01       Impact factor: 9.139

4.  Pulmonary clearance of 99mTc-DTPA: influence of background activity.

Authors:  M P Barrowcliffe; C Otto; J G Jones
Journal:  J Appl Physiol (1985)       Date:  1988-03

5.  Respiratory mucosal permeability in asthma.

Authors:  R K Elwood; S Kennedy; A Belzberg; J C Hogg; P D Paré
Journal:  Am Rev Respir Dis       Date:  1983-09

6.  Respiratory clearance of 99mTc-DTPA and pulmonary involvement in sarcoidosis.

Authors:  D J Dusser; M A Collignon; G Stanislas-Leguern; L G Barritault; J Chrétien; G J Huchon
Journal:  Am Rev Respir Dis       Date:  1986-09

7.  Increased airway mucosal permeability of smokers. Relationship to airway reactivity.

Authors:  S M Kennedy; R K Elwood; B J Wiggs; P D Paré; J C Hogg
Journal:  Am Rev Respir Dis       Date:  1984-01

8.  Effect of increases in lung volume on clearance of aerosolized solute from human lungs.

Authors:  J D Marks; J M Luce; N M Lazar; J N Wu; A Lipavsky; J F Murray
Journal:  J Appl Physiol (1985)       Date:  1985-10

9.  Exercise increases the lung clearance of inhaled technetium-99m DTPA.

Authors:  M Meignan; J Rosso; J Leveau; A Katz; L Cinotti; G Madelaine; P Galle
Journal:  J Nucl Med       Date:  1986-02       Impact factor: 10.057

10.  Regional respiratory clearance of aerosolized 99mTc-DTPA: posture and smoking effects.

Authors:  D J Dusser; B D Minty; M A Collignon; D Hinge; L G Barritault; G J Huchon
Journal:  J Appl Physiol (1985)       Date:  1986-06
View more
  11 in total

Review 1.  Waiting to inhale: noninjectable insulin, are we there yet?

Authors:  Kjeld Hermansen
Journal:  Curr Diab Rep       Date:  2004-10       Impact factor: 4.810

2.  Site of deposition and absorption of an inhaled hydrophilic solute.

Authors:  Eva Bondesson; Thomas Bengtsson; Lars-Erik Nilsson; Per Wollmer
Journal:  Br J Clin Pharmacol       Date:  2007-01-23       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of salmeterol.

Authors:  Mario Cazzola; Renato Testi; Maria Gabriella Matera
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Surface active agents as enhancers of alveolar absorption.

Authors:  P Wollmer; K Bäckström; H Zhao; P G Nilsson; B Jonson
Journal:  Pharm Res       Date:  2000-01       Impact factor: 4.200

5.  Effects of sodium taurocholate on the absorption of inhaled 99mTc-DTPA.

Authors:  Eva Bondesson; Thomas Bengtsson; Lars-Erik Nilsson; Per Wollmer
Journal:  Pharm Res       Date:  2006-08-11       Impact factor: 4.200

Review 6.  Clinical pharmacokinetics of terbutaline in humans: a systematic review.

Authors:  Khadeeja Sultan; Ammara Zamir; Waseem Ashraf; Imran Imran; Hamid Saeed; Anees Ur Rehman; Abdul Majeed; Muhammad Fawad Rasool
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-10-13       Impact factor: 3.195

Review 7.  Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives.

Authors:  Ruzena Tkacova
Journal:  Mediators Inflamm       Date:  2010-04-20       Impact factor: 4.711

8.  Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics.

Authors:  Robert Fountaine; Ashley Milton; Tina Checchio; Greg Wei; Marilyn Stolar; John Teeter; Rudolph Jaeger; David Fryburg
Journal:  Br J Clin Pharmacol       Date:  2008-06       Impact factor: 4.335

Review 9.  Pharmacokinetic optimisation of asthma treatment.

Authors:  A M Taburet; B Schmit
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

10.  Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study.

Authors:  Christopher I Whale; Milind P Sovani; Kevin J Mortimer; Timothy W Harrison; Anne E Tattersfield
Journal:  Br J Clin Pharmacol       Date:  2008-04-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.